To assess CAR activity against target tumors, EphA2 CAR-NK92 cells were cocultured in vitro with three tumor cell lines: H460 (human lung cancer), MDA-MB-231 (human breast cancer), and K562 (Chronic Myelogenous Leukemia). This evidence concerns the gene EPHA2 and chronic myelogenous leukemia, BCR-ABL1 positive.